Tecentriq

(Atezolizumab)

ApprovedMonoclonal antibody

Atezolizumab is used to treat certain types of cancer, including lung cancer, bladder cancer, and breast cancer, by helping the body's immune system recognize and fight cancer cells.[2] Tecentriq is currently approved and in use across 142 indications[4].[1]

Tecentriq is one of 1821 monoclonal antibody programs targeting Glioma. It is currently in Approved.

142

Indications

676

Total Trials

Active Trials

1,820

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Small Cell CarcinomaRecruiting

Pancreatic NeoplasmActive, not recruiting

Urinary Bladder CarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

Non-Hodgkins LymphomaActive, not recruiting

MetastasisActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Prostate AdenocarcinomaActive, not recruiting

Esophageal CarcinomaActive, not recruiting

GliomaPhase 1

Active, not recruiting

Small Cell CarcinomaPhase 2

Recruiting

Pancreatic NeoplasmPhase 1

Active, not recruiting

Urinary Bladder CarcinomaPhase 3

Active, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

Non-Hodgkins LymphomaPreclinical

Active, not recruiting

MetastasisPhase 2

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 3

Active, not recruiting

Prostate AdenocarcinomaPhase 3

Active, not recruiting

Esophageal CarcinomaPhase 3

Active, not recruiting

Showing 10 of 142 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Approved

36 2

Tykerb

GSK

Preclinical

80 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

MS Contin

Merck & Co.

Preclinical

2 5

Lexiscan

Astellas

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 9

Spravato

WWim Janssens

Preclinical

2 10

Chantix

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer

NCT04563338

Phase 3Active, not recruiting

Hepatocellular Carcinoma

NCT05904886

Phase 2Active, not recruiting

Prostate Cancer

NCT04262154

Phase 2Active, not recruiting

Endometrial Cancer

NCT03526432

Phase 2Active, not recruiting

Glioblastoma

NCT04729959

Phase 3Active, not recruiting

Bladder Cancer

NCT04660344

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer28 trials

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT03563716·135 enrolled

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Completed· Roche logo

Roche·Phase 2·NCT01846416·138 enrolled

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Completed· Roche logo

Roche·Phase 3·NCT02409342·572 enrolled

Show 25 more trials

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Completed· Roche logo

Roche·Phase 3·NCT03456063·453 enrolled

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

Completed· Roche logo

Roche·Phase 2·NCT02927301·181 enrolled

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1/2·NCT03023423·100 enrolled

A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 3·NCT03922997·101 enrolled

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03337698·314 enrolled

An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)

Active, not recruiting·UUniversity Health Network, Toronto·Phase 2·NCT04563338·36 enrolled

A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT02813785·565 enrolled

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Active, not recruiting·NNational Taiwan University Hospital·Phase 2·NCT04147351·22 enrolled

Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer

Unknown status·YYonsei University·Phase 2·NCT05034055·45 enrolled

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT03191786·453 enrolled

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Active, not recruiting·UUniversity of Southern California·Phase 2·NCT05340309·5 enrolled

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT02366143·1,202 enrolled

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT02367781·723 enrolled

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04989283

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Completed· Pfizer logo

Pfizer··NCT05834348·5,279 enrolled

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT05171777·179 enrolled

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

Terminated·IImugene Limited·Phase 1·NCT04432207·24 enrolled

A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)

Terminated· Roche logo

Roche·Phase 3·NCT02409355·8 enrolled

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

Terminated·MMayo Clinic·Phase 1·NCT03455556·1 enrolled

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

Completed· Roche logo

Roche·Phase 3·NCT02008227·1,225 enrolled

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Withdrawn·UUniversity of Washington·Phase 2·NCT05935774

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Active, not recruiting·DDwight Owen·Phase 1·NCT04919369·18 enrolled

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Completed· Roche logo

Roche·Phase 3·NCT02657434·578 enrolled

Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

Completed· Regeneron logo

Regeneron·Phase 1·NCT03438318·29 enrolled

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Recruiting·EEmory University·Phase 2·NCT06731270·20 enrolled

Breast Cancer13 trials

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT03199885·190 enrolled

Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer

Completed·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT05609903·52 enrolled

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03197935·333 enrolled

Show 10 more trials

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

Active, not recruiting·SSOLTI Breast Cancer Research Group·Phase 2·NCT04759248·55 enrolled

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Completed· Roche logo

Roche·Phase 3·NCT03125902·653 enrolled

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Recruiting·GGerman Cancer Research Center·Phase 2·NCT05332561·240 enrolled

Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

Recruiting·EEuropean Institute of Oncology·Phase 2·NCT06690840·45 enrolled

Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer

Completed·SSOLTI Breast Cancer Research Group·Phase 1·NCT03802604·28 enrolled

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy

Completed· Roche logo

Roche·Phase 2·NCT02924883·202 enrolled

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Active, not recruiting·NNational Cancer Center, Korea·Phase 2·NCT03756298·284 enrolled

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Terminated·VVanderbilt-Ingram Cancer Center·Phase 1/2·NCT03566485·12 enrolled

Pre-operative Immunotherapy Combination Strategies in Breast Cancer

Completed·QQueen Mary University of London·Phase 2·NCT03395899·71 enrolled

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Active, not recruiting· Roche logo

Roche··NCT04158258·2,907 enrolled

Small Cell Lung Cancer9 trials

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT06287775·45 enrolled

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

Recruiting·SSe-Hoon Lee·Phase 2·NCT06830694·50 enrolled

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Completed· Roche logo

Roche·Phase 3·NCT02763579·503 enrolled

Show 6 more trials

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT03830918·59 enrolled

Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04462276·68 enrolled

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Recruiting· Amgen logo

Amgen·Phase 1·NCT06898957·200 enrolled

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 3·NCT04256421·490 enrolled

Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04696939·100 enrolled

Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

Unknown status·FFundacion Oncosur·Phase 1/2·NCT04253145·184 enrolled

Hepatocellular Carcinoma8 trials

Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma

Completed·SSun Yat-sen University··NCT06199297·188 enrolled

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Unknown status·—··NCT05173298·100 enrolled

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy

Completed·—··NCT05197504·166 enrolled

Show 5 more trials

β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07317414·158 enrolled

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Suspended·NNorthwestern University·Phase 2·NCT05620771·84 enrolled

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05904886·687 enrolled

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Recruiting·—·Phase 2·NCT05528952·105 enrolled

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Completed· Roche logo

Roche·Phase 3·NCT03434379·558 enrolled

Bladder Cancer8 trials

Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer

Active, not recruiting·DDeepak Kilari·Phase 2·NCT04289779·46 enrolled

Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

Unknown status·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2·NCT03620435·25 enrolled

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Completed· Roche logo

Roche·Phase 3·NCT02302807·931 enrolled

Show 5 more trials

CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Completed·BBavarian Nordic·Phase 2·NCT03628716·43 enrolled

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04660344·761 enrolled

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02989584·54 enrolled

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)

Completed· Roche logo

Roche·Phase 2·NCT02108652·310 enrolled

Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

Active, not recruiting·UUNICANCER·Phase 3·NCT03799835·517 enrolled

75 more indications

Urothelial Carcinoma7 trials

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03513952·47 enrolled

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma

Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT04602078·82 enrolled

A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

Completed· Roche logo

Roche·Phase 3·NCT02928406·1,004 enrolled

Show 4 more trials

A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)

Terminated· Roche logo

Roche··NCT03399643·22 enrolled

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT03179943·21 enrolled

A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina

Completed· Roche logo

Roche··NCT03330886·13 enrolled

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Completed· Roche logo

Roche·Phase 1/2·NCT03869190·272 enrolled

Triple-Negative Breast Cancer6 trials

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Terminated· Roche logo

Roche·Phase 2·NCT02322814·169 enrolled

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Active, not recruiting·—·Phase 2·NCT03483012·6 enrolled

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03371017·595 enrolled

Show 3 more trials

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Completed· Roche logo

Roche·Phase 3·NCT02425891·902 enrolled

A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT04148911·184 enrolled

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT04584112·83 enrolled

Bevacizumab6 trials

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Terminated·RReplimune Inc.·Phase 2·NCT05733611·5 enrolled

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Completed·—··NCT04862949·131 enrolled

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients

Completed·FFundación GECP·Phase 2·NCT03836066·41 enrolled

Show 3 more trials

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

Recruiting·UUniversity of Alabama at Birmingham·Phase 1/2·NCT06294548·45 enrolled

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Completed·MMedical College of Wisconsin·Phase 2·NCT03694262·30 enrolled

Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC

Unknown status·SSamsung Medical Center·Phase 2·NCT03616691·46 enrolled

Metastatic Colorectal Cancer4 trials

Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer

Unknown status·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT04659382·52 enrolled

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

Active, not recruiting·EExelixis·Phase 3·NCT05425940·901 enrolled

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 3·NCT06733038·238 enrolled

Show 1 more trial

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Terminated· Roche logo

Roche·Phase 1/2·NCT03555149·96 enrolled

Renal Cell Carcinoma4 trials

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

Completed· Roche logo

Roche·Phase 2·NCT01984242·305 enrolled

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Completed· Roche logo

Roche·Phase 3·NCT02420821·915 enrolled

Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

Completed· Roche logo

Roche·Phase 1·NCT03063762·69 enrolled

Show 1 more trial

Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Completed·—·Phase 2·NCT02724878·65 enrolled

Immunotherapy4 trials

Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab

Recruiting·RRegina Elena Cancer Institute·Phase 2·NCT06771518·37 enrolled

SIRT and Peri-immunotherapy : a New Concept

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris··NCT06971237·60 enrolled

Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)

Not yet recruiting·—·Phase 3·NCT06719336·182 enrolled

Show 1 more trial

FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction

Not yet recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT05703997·20 enrolled

Melanoma4 trials

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Active, not recruiting·UUnknown Sponsor·Phase 2·NCT04722575·95 enrolled

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Terminated· Roche logo

Roche·Phase 3·NCT03273153·446 enrolled

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

Completed· Roche logo

Roche·Phase 1·NCT03178851·155 enrolled

Show 1 more trial

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Active, not recruiting·MMayo Clinic·Phase 2·NCT03554083·59 enrolled

Endometrial Cancer3 trials

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Recruiting·AAlliance Foundation Trials, LLC.·Phase 1/2·NCT04486352·148 enrolled

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

Active, not recruiting·UUniversity of Oklahoma·Phase 2·NCT03526432·110 enrolled

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT05542407·58 enrolled

Lymphoma3 trials

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Terminated· Roche logo

Roche·Phase 1/2·NCT05315713·8 enrolled

Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma

Terminated·TThe Lymphoma Academic Research Organisation·Phase 1·NCT03892525·4 enrolled

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

Completed·OOrphAI Therapeutics·Phase 1·NCT02594384·62 enrolled

Ovarian Cancer3 trials

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Withdrawn·UUniversity Health Network, Toronto·Phase 2·NCT04510584

ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

Completed·AARCAGY/ GINECO GROUP·Phase 3·NCT02891824·614 enrolled

Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

Completed·GGrupo Español de Investigación en Cáncer de Ovario·Phase 3·NCT03598270·417 enrolled

Liver Cancer3 trials

Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

Recruiting·UUniversity Health Network, Toronto·Phase 1/2·NCT06725121·48 enrolled

A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev

Active, not recruiting·JJia Fan·Phase 3·NCT04649489·501 enrolled

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

Recruiting·MMichael Dill·Phase 2·NCT05690048·48 enrolled

Prostate Cancer3 trials

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT04272645

Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Completed·UUniversity of Hawaii·Phase 1·NCT03024216·37 enrolled

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04262154·28 enrolled

Advanced Solid Tumors3 trials

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Completed·AAdlai Nortye Biopharma Co., Ltd.·Phase 1·NCT04975958·47 enrolled

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Active, not recruiting· Amgen logo

Amgen·Phase 1·NCT04185883·610 enrolled

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Terminated·DDracen Pharmaceuticals, Inc.·Phase 1/2·NCT04471415·61 enrolled

Efficacy and Safety3 trials

Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC

Not yet recruiting·FFuzhou General Hospital··NCT07093762·35 enrolled

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Active, not recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 3·NCT05468489·200 enrolled

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Active, not recruiting· Roche logo

Roche·Phase 2·NCT04931342·176 enrolled

Treatment3 trials

Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice

Terminated· Roche logo

Roche·Phase 2/3·NCT05694013·49 enrolled

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT04637594·3 enrolled

SMMART Adaptive Clinical Treatment (ACT) Trial

Withdrawn·OOHSU Knight Cancer Institute·Phase 1·NCT05238831

Lung Cancer3 trials

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06807632·24 enrolled

Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer

Completed·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT04730999·54 enrolled

Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT04631029·3 enrolled

Immune3 trials

Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT03612791·189 enrolled

Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT03421288·677 enrolled

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC

Withdrawn·WWashington University School of Medicine·Phase 2·NCT05007769

Metastatic Solid Tumors2 trials

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Terminated· Roche logo

Roche·Phase 2·NCT03386721·256 enrolled

A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT04303858·189 enrolled

Chemotherapy2 trials

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

Recruiting·SSun Yat-sen University·Phase 2·NCT07192185·30 enrolled

A Study on the Efficacy of Atezolizumab Combined with Chemotherapy

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China··NCT06780826·1,430 enrolled

Immune Checkpoint Blockade2 trials

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Withdrawn·GGritstone bio, Inc.·Phase 2·NCT05456165

Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

Terminated·—·Phase 1/2·NCT04214418·27 enrolled

Cervical Cancer2 trials

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03614949·21 enrolled

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

Completed·NNykode Therapeutics ASA·Phase 2·NCT04405349·52 enrolled

Pancreatic Ductal Adenocarcinoma2 trials

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting·NNovoCure GmbH·Phase 2·NCT06390059·84 enrolled

Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma

Terminated·GGulam Manji·Phase 2·NCT03979066·1 enrolled

Advanced NSCLC2 trials

Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

Active, not recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT05781308·156 enrolled

Atezolizumab Immunotherapy in Patients With Advanced NSCLC

Completed·AAlliance Foundation Trials, LLC.·Phase 2·NCT03102242·64 enrolled

Colorectal Cancer2 trials

Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

Active, not recruiting·TTreos Bio Limited·Phase 2·NCT05243862·18 enrolled

Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer

Withdrawn·NNiharika Mettu·Phase 2·NCT03340558

Locally Advanced or Metastatic Solid Tumors2 trials

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Terminated· Roche logo

Roche·Phase 1·NCT06488716·12 enrolled

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02174172·158 enrolled

Cancer2 trials

Improving Public Cancer Care by Implementing Precision Medicine in Norway

Recruiting·OOslo University Hospital·Phase 2·NCT04817956·3,000 enrolled

A MolEcularly Guided Anti-Cancer Drug Off-Label Trial

Active, not recruiting·UUppsala University Hospital·Phase 2·NCT04185831·167 enrolled

Neoadjuvant Treatment2 trials

Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)

Active, not recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT04017455·38 enrolled

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Terminated·FFundación GECP·Phase 2·NCT04512430·4 enrolled

Locally Advanced or Metastatic NSCLC1 trial

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Active, not recruiting·NNeoImmuneTech·Phase 2·NCT04984811·83 enrolled

Mucosal Melanoma1 trial

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Completed· Roche logo

Roche·Phase 2·NCT04091217·43 enrolled

Multiple Myeloma1 trial

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Completed· Roche logo

Roche·Phase 1·NCT02431208·85 enrolled

Effectiveness1 trial

The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

Completed·SSun Yat-sen University·N/A·NCT07272265·300 enrolled

Portal vein thrombosis1 trial

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Recruiting·—·Phase 2·NCT06823375·40 enrolled

Brachytherapy1 trial

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Recruiting·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT05984511·234 enrolled

Advanced Stage Cancer1 trial

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting·AAmerican Society of Clinical Oncology·Phase 2·NCT02693535·4,200 enrolled

Myelodysplastic Syndromes1 trial

A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes

Completed· Roche logo

Roche·Phase 1·NCT02508870·46 enrolled

Kidney Cancer1 trial

Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

Terminated·UUniversity of Washington·Phase 2·NCT03050060·21 enrolled

Squamous Cell Carcinoma1 trial

Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).

Unknown status·UUniversity Hospital Southampton NHS Foundation Trust·Phase 2·NCT05038657·36 enrolled

Esophageal Adenocarcinoma1 trial

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03784326·43 enrolled

Drug Safety1 trial

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Completed· Roche logo

Roche··NCT03232593·1,758 enrolled

Genitourinary Cancer1 trial

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT03115801·6 enrolled

Malignant Pleural Mesothelioma1 trial

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

Recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 3·NCT04996017·162 enrolled

Trial1 trial

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

MPA1 trial

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

Terminated·PPalleos Healthcare GmbH·Phase 2·NCT04770272·442 enrolled

Macrovascular Invasion1 trial

Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

Recruiting·—·Phase 2·NCT05992220·138 enrolled

Non-squamous NSCLC1 trial

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

Recruiting·UUniversity Hospital Heidelberg·Phase 2·NCT04865250·20 enrolled

Richter Transformation1 trial

ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting·NNiguarda Hospital·Phase 2·NCT04082897·28 enrolled

Unresectable1 trial

Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

Recruiting·TTuen Mun Hospital·Phase 2/3·NCT07293468·106 enrolled

Unknown status·HHospices Civils de Lyon·Phase 2·NCT04739202·60 enrolled

Radiation Therapy1 trial

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Terminated·RRutgers, The State University of New Jersey·Phase 1·NCT04081688·16 enrolled

Colorectal Adenocarcinoma1 trial

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

Completed· Roche logo

Roche·Phase 3·NCT02788279·363 enrolled

Anal Carcinoma1 trial

Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)

Recruiting·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT05661188·45 enrolled

Metastatic1 trial

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Terminated·AAffimed GmbH·Phase 1/2·NCT05109442·112 enrolled

Malignant Mesothelioma1 trial

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

Unknown status·UUniversity of Leicester·Phase 2·NCT03654833·186 enrolled

Capecitabine1 trial

Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

Active, not recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT03448835·20 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04543617·760 enrolled

Liver Transplant1 trial

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT07059494·40 enrolled

Thymic Carcinoma1 trial

A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma

Completed· Roche logo

Roche·Phase 2·NCT04321330·34 enrolled

Neuroendocrine Cancer1 trial

A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

Active, not recruiting·TTechnische Universität Dresden·Phase 2·NCT05470595·67 enrolled

ES-SCLC1 trial

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Recruiting·RRayzeBio, Inc.·Phase 1·NCT05595460·49 enrolled

Immunogenicity1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Terminated· Roche logo

Roche·Phase 1/2·NCT02541604·87 enrolled

Biliary Tract Cancer1 trial

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04941287·57 enrolled

Pancreatic Cancer1 trial

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04161755·29 enrolled

Glioblastoma1 trial

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04729959·59 enrolled

Carboplatin1 trial

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

Withdrawn· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT06719973

Osteosarcoma1 trial

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

Recruiting·EEmory University·Phase 1·NCT06492954·12 enrolled

Efficacy1 trial

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Terminated· BioNTech logo

BioNTech·Phase 1/2·NCT04101357·54 enrolled

NSCLC1 trial

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

Recruiting·UUniversity of Kansas Medical Center·Phase 1/2·NCT04467723·25 enrolled

Papilloma1 trial

Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)

Completed·—·Phase 2·NCT03946358·47 enrolled

Advanced Cancers1 trial

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT04902040·19 enrolled

Infusion1 trial

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Recruiting·IIsala·Phase 4·NCT06031233·679 enrolled

Malignant Glioma1 trial

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Withdrawn·DDarell Bigner·Phase 1/2·NCT03973879

Unspecified2 trials

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Active, not recruiting·NNancy Lin, MD·Phase 2·NCT03417544·19 enrolled

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03768063·1,000 enrolled

Regulatory

FDA Approval Timeline[5]

May 18, 2016

Tecentriq

BLA 761034

May 18, 2016

TECENTRIQ

BLA BLA761034

Sources

References

[1]
ClinicalTrials.gov — 676 trial records for Atezolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Tecentriq drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Atezolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Atezolizumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA 761034). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: PD-L1 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Roche

Tecentriq

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Non-Small Cell Lung Cancer28 trials

Breast Cancer13 trials

Small Cell Lung Cancer9 trials

Hepatocellular Carcinoma8 trials

Bladder Cancer8 trials

Urothelial Carcinoma7 trials

Triple-Negative Breast Cancer6 trials

Bevacizumab6 trials

Metastatic Colorectal Cancer4 trials

Renal Cell Carcinoma4 trials

Immunotherapy4 trials

Melanoma4 trials

Endometrial Cancer3 trials

Lymphoma3 trials

Ovarian Cancer3 trials

Liver Cancer3 trials

Prostate Cancer3 trials

Advanced Solid Tumors3 trials

Efficacy and Safety3 trials

Treatment3 trials

Lung Cancer3 trials

Immune3 trials

Metastatic Solid Tumors2 trials

Chemotherapy2 trials

Immune Checkpoint Blockade2 trials

Cervical Cancer2 trials

Pancreatic Ductal Adenocarcinoma2 trials

Advanced NSCLC2 trials

Colorectal Cancer2 trials

Locally Advanced or Metastatic Solid Tumors2 trials

Cancer2 trials

Neoadjuvant Treatment2 trials

Locally Advanced or Metastatic NSCLC1 trial

Mucosal Melanoma1 trial

Multiple Myeloma1 trial

Effectiveness1 trial

Portal vein thrombosis1 trial

Brachytherapy1 trial

Advanced Stage Cancer1 trial

Myelodysplastic Syndromes1 trial

Kidney Cancer1 trial

Squamous Cell Carcinoma1 trial

Esophageal Adenocarcinoma1 trial

Drug Safety1 trial

Genitourinary Cancer1 trial

Malignant Pleural Mesothelioma1 trial

Trial1 trial

MPA1 trial

Macrovascular Invasion1 trial

Non-squamous NSCLC1 trial

Richter Transformation1 trial

Unresectable1 trial

Fecal Microbiota Transplantation1 trial

Systemic Therapy1 trial

Tumors1 trial

Gastric Adenocarcinoma1 trial

Radiation Therapy1 trial

Colorectal Adenocarcinoma1 trial

Anal Carcinoma1 trial

Metastatic1 trial

Malignant Mesothelioma1 trial

Capecitabine1 trial

Esophageal Squamous Cell Carcinoma1 trial

Liver Transplant1 trial

Thymic Carcinoma1 trial

Neuroendocrine Cancer1 trial

ES-SCLC1 trial

Immunogenicity1 trial

Biliary Tract Cancer1 trial

Pancreatic Cancer1 trial

Glioblastoma1 trial

Carboplatin1 trial

Osteosarcoma1 trial

Efficacy1 trial